- Home
- BXSL vs HALO Comparison
BXSL vs HALO Comparison
Compare BXSL & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BXSL | HALO |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 7.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BXSL | HALO |
|---|---|---|
| Price | $28.15 | $62.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | $29.38 | ★ $73.33 |
| AVG Volume (30 Days) | 1.4M | ★ 2.5M |
| Earning Date | 11-10-2025 | 11-03-2025 |
| Dividend Yield | ★ 10.93% | N/A |
| EPS Growth | N/A | ★ 56.68 |
| EPS | 2.66 | ★ 4.74 |
| Revenue | ★ $1,413,784,000.00 | $1,242,852,000.00 |
| Revenue This Year | $9.05 | $34.83 |
| Revenue Next Year | $0.28 | $24.84 |
| P/E Ratio | ★ $10.60 | $13.14 |
| Revenue Growth | 10.58 | ★ 31.19 |
| 52 Week Low | $24.85 | $46.26 |
| 52 Week High | $34.64 | $79.50 |
Technical Indicators
Market Signals| Indicator | BXSL | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 64.79 | 34.09 |
| Support Level | $28.03 | $61.23 |
| Resistance Level | $28.57 | $63.26 |
| Average True Range (ATR) | 0.40 | 2.42 |
| MACD | 0.07 | -0.79 |
| Stochastic Oscillator | 80.18 | 7.60 |
Price Performance
Historical ComparisonAbout BXSL Blackstone Secured Lending Fund of Beneficial Interest
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.